Autres langues Pliant Therapeutics, Inc.

Actions

PLRX

US7291391057

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
11,81 ^USD	-0,59%		-5,67%	-34,79%

12/03	Pliant Therapeutics, Inc. annonce un plan de développement accéléré du Bexotegrast pour le traitement de la fibrose pulmonaire idiopathique	CI
05/03	PLIANT THERAPEUTICS, INC. : RBC Capital Markets toujours positif	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pliant Therapeutics to Participate in Upcoming Investor Events	02/04
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference	27/03
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	13/03
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12/03
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12/03
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12/03
Pliant Therapeutics : March 2024 Corporate Presentation	29/02
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	27/02
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	27/02
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Pliant Therapeutics to Participate in Upcoming Investor Conferences	26/02
Pliant Therapeutics to Participate in Upcoming Investor Conferences	26/02
Pliant Therapeutics to Participate in Upcoming Investor Events	07/02
Pliant Therapeutics to Participate in Upcoming Investor Events	07/02
Pliant Therapeutics Reports Interim 'Positive' Safety, Efficacy Data for Potential Liver Disease Drug	05/02
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	04/02
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	04/02
Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis	04/02
Pliant Therapeutics Insider Sold Shares Worth $443,173, According to a Recent SEC Filing	19/01
Top Premarket Decliners	11/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Pliant Therapeutics, Inc.

Actions

PLRX

US7291391057

Autres langues

Filtres